Patients treated with trastuzumab deruxtecan ... in combination with pertuzumab as a first-line treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

trastuzumab and pertuzumab (THP) as a 1st-line treatment for patients with HER2-positive metastatic breast cancer. The PFS improvement was seen across all pre-specified patient subgroups with ...

Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (trastuzumab ...

after showing that the combination of Enhertu (trastuzumab deruxtecan) with Roche's anti-HER2 antibody Perjeta (pertuzumab) was better at extending the time to cancer progression or death in ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) in patients with HER2-positive ...

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer. First-line treatment with Enhertu (fam-trastuzumab ...

Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab ... receptor 2 (HER2)-positive metastatic breast cancer. In the trial, the combination was compared to taxane, trastuzumab and pertuzumab ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) either alone or in combination with pertuzumab versus standard of care ...